Valneva SE – NASDAQ:VALN
Valneva SE stock price today
$11.47
+7.14
+164.9%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 8 hours
Valneva SE stock price monthly change
-42.95%
month
Valneva SE stock price quarterly change
-42.95%
quarter
Valneva SE stock price yearly change
-59.15%
year
Valneva SE key metrics
Market Cap | 328.85M |
Enterprise value | 418.59M |
P/E | -3.87 |
EV/Sales | 0.79 |
EV/EBITDA | 4.37 |
Price/Sales | 0.83 |
Price/Book | 2.66 |
PEG ratio | -0.07 |
EPS | -0.18 |
Revenue | 152.95M |
EBITDA | -86.93M |
Income | -24.39M |
Revenue Q/Q | -2.25% |
Revenue Y/Y | -58.98% |
Profit margin | 13.9% |
Oper. margin | 22.55% |
Gross margin | 56.25% |
EBIT margin | 22.55% |
EBITDA margin | -56.84% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeValneva SE stock price history
Valneva SE stock forecast
Valneva SE financial statements
| Jun 2023 | 40.23M | -16.91M | -42.05% |
|---|---|---|---|
| Sep 2023 | 38.07M | -34.22M | -89.9% |
| Dec 2023 | 41.89M | -32.15M | -76.75% |
| Mar 2024 | 32.75M | 58.90M | 179.86% |
| 2027 | 444.69M | 136.99M | 30.81% |
|---|
Analysts Price target
Financials & Ratios estimates
| 2022-11-10 | -0.14 | 1.33 |
|---|---|---|
| 2023-03-23 | -0.65 | -0.65 |
| 2023-05-04 | -0.34 | -0.54 |
| Jun 2023 | 542571000 | 351.86M | 64.85% |
|---|---|---|---|
| Sep 2023 | 520539000 | 363.01M | 69.74% |
| Dec 2023 | 469391000 | 341.14M | 72.68% |
| Mar 2024 | 502829000 | 313.60M | 62.37% |
| Jun 2023 | -41.10M | -3.07M | -5.66M |
|---|---|---|---|
| Sep 2023 | -71.40M | 2.36M | 35.61M |
| Dec 2023 | -69.22M | -16.80M | 40.74M |
| Mar 2024 | -34.00M | 86.44M | -1.62M |
Valneva SE alternative data
| Aug 2023 | 719 |
|---|---|
| Sep 2023 | 719 |
| Oct 2023 | 700 |
| Nov 2023 | 700 |
| Dec 2023 | 719 |
| Jan 2024 | 719 |
| Feb 2024 | 719 |
| Mar 2024 | 676 |
| Apr 2024 | 676 |
| May 2024 | 676 |
| Jun 2024 | 676 |
| Jul 2024 | 676 |
Valneva SE other data
0.32%
-0.09%
of VALN is owned by hedge funds
374.97K
-30.90K
shares is hold by hedge funds
| Quarter | Transcript |
|---|---|
| Q4 2023 20 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 9 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 21 Sep 2023 | Q2 2023 Earnings Call Transcript |
| Q1 2023 6 May 2023 | Q1 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. David Lawrence (1963) Acting Chief Financial Officer | $1,300,000 |
Mr. Thomas Lingelbach (1963) Chairman of the Management Board, Pres & Chief Executive Officer | $732,960 |
Mr. Franck Grimaud MBA (1967) Pres, Chief Bus. Officer & Member of Management Board | $461,200 |
Dr. Juan-Carlos Jaramillo M.D. (1971) Chief Medical Officer & Member of the Management Board | $370,870 |
Mr. Frederic Jacotot (1965) Vice President of Legal & IP, Gen. Counsel, Corporation Sec. and Member of Management Board | $350,650 |
Valneva Is A 'Buy' As A First-Mover In Chikungunya
Valneva's Vaccination Valor: A Buy Rating Justified
Valneva: VLA1553 Takes The Lead In The Chikungunya Vaccine Race
Valneva Q4: Resilient Pipeline And Partnership With Pfizer, Reinforcing A Promising Future
Valneva SE: Underfollowed French Biotech, 2 Interesting Vaccine Approvals Expected In 2023
Bavarian Nordic A/S Could Post A Strong Comeback
Valneva: Vaccine Business, Catalysts Ahead, And Pfizer's Lyme Love
Dynavax Technologies: Full Speed Ahead
-
What's the price of Valneva SE stock today?
One share of Valneva SE stock can currently be purchased for approximately $11.47.
-
When is Valneva SE's next earnings date?
Unfortunately, Valneva SE's (VALN) next earnings date is currently unknown.
-
Does Valneva SE pay dividends?
No, Valneva SE does not pay dividends.
-
How much money does Valneva SE make?
Valneva SE has a market capitalization of 328.85M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 57.46% to 153.71M US dollars. Valneva SE made a loss 101.43M US dollars in net income (profit) last year or -$0.54 on an earnings per share basis.
-
What is Valneva SE's stock symbol?
Valneva SE is traded on the NASDAQ under the ticker symbol "VALN".
-
What is Valneva SE's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Valneva SE?
Shares of Valneva SE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Valneva SE's key executives?
Valneva SE's management team includes the following people:
- Mr. David Lawrence Acting Chief Financial Officer(age: 62, pay: $1,300,000)
- Mr. Thomas Lingelbach Chairman of the Management Board, Pres & Chief Executive Officer(age: 62, pay: $732,960)
- Mr. Franck Grimaud MBA Pres, Chief Bus. Officer & Member of Management Board(age: 58, pay: $461,200)
- Dr. Juan-Carlos Jaramillo M.D. Chief Medical Officer & Member of the Management Board(age: 54, pay: $370,870)
- Mr. Frederic Jacotot Vice President of Legal & IP, Gen. Counsel, Corporation Sec. and Member of Management Board(age: 60, pay: $350,650)
-
How many employees does Valneva SE have?
As Jul 2024, Valneva SE employs 676 workers.
-
When Valneva SE went public?
Valneva SE is publicly traded company for more then 4 years since IPO on 5 May 2021.
-
What is Valneva SE's official website?
The official website for Valneva SE is valneva.com.
-
How can i contact Valneva SE?
Valneva SE can be reached via phone at +33 2 28 07 37 10.
Valneva SE company profile:
Valneva SE
valneva.comExchange:
NASDAQ
Full time employees:
676
Industry:
Biotechnology
Sector:
Healthcare
Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.
6 rue Alain Bombard
Saint-Herblain, 44800
Saint-Herblain, 44800
CIK: 0001836564
ISIN: US92025Y1038
CUSIP: 92025Y103
